ACHILLION PHARMACEUTICALS INC
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | $15.0M | $66.1M | $0 | $0 |
| Operating income | −$75.9M | −$89.6M | −$64.9M | −$15.1M | −$69.4M | −$59.5M |
| Net income | −$20.6M | −$20.2M | −$61.7M | −$5.0M | −$69.0M | −$58.9M |
| Total assets | $277.9M | $337.6M | $413.9M | $464.5M | $156.8M | $162.4M |
| Total liabilities | $11.8M | $13.1M | $14.4M | $14.9M | $13.3M | $9.5M |
| Equity | $266.0M | $324.5M | $399.5M | $449.6M | $143.5M | $153.0M |
| EPS (diluted) | — | — | — | — | — | — |
| Shares out. | 137.9M | 136.7M | 136.6M | 117.5M | 96.8M | 79.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2018- Operating margin
- —
- Net margin
- —
- Return on equity
- −7.7%
- Return on assets
- −7.4%
- Return on capital (ROCE)
- −28.5%
- Liabilities / assets
- 4.3%
- Debt / equity
- 0.04×
- Book value / share
- $1.93
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2018- Altman Z″ (distress)
- 20.07safe
- Accruals / assets
- 14.9%high accruals
- Piotroski F-Score
- 0/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 warning● 2 good- Negative operating cash flow
- High accruals — earnings-quality risk
- Conservative leverage (liabilities < 50% of assets)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsJan 28, 2020
- Other material eventJan 24, 2020
- Other material eventJan 16, 2020
- Shareholder vote · Other material eventDec 19, 2019
- Results of operations · Other material eventNov 7, 2019
- Entered a material agreement · Amended charter or bylaws · Other material eventOct 16, 2019
- Entered a material agreement · New financial obligationSep 17, 2019
- Results of operationsAug 8, 2019
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/ASEC SCHEDULE 13GFeb 16, 2021
- SC 13GFeb 14, 2020
- SC 13G/AFeb 14, 2020
- SC 13G/ASCHEDULE 13G/AFeb 12, 2020
- SC 13G/ASCHEDULE 13G/AFeb 12, 2020
- SC 13G/AFeb 10, 2020
- 15-12BFeb 7, 2020
- EFFECTJan 31, 2020
- EFFECTJan 31, 2020
- EFFECTJan 31, 2020
- EFFECTJan 31, 2020
- 4Jan 30, 2020
- 3Jan 30, 2020
- 4PRIMARY DOCUMENTJan 29, 2020
- 4PRIMARY DOCUMENTJan 29, 2020
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.